Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.59    -0.31 (-10.69%)
Bid:
2.60
Ask:
2.91
Spread: 0.31 (11.923%)
Market Cap: £4.73m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Corporate Update

27 Sep 2013 07:00

RNS Number : 0608P
Nanoco Group PLC
27 September 2013
 



For immediate release

27 September 2013

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Corporate Update

 

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, is pleased to announce the following corporate update.

 

Nanoco has completed the planned expansion of its cadmium-free quantum dot production facility in Runcorn with the installation and commissioning of two further Semi-Tech lines at a planned cost of approximately £1.25 million.

 

These Semi-Tech lines will be used to fulfil orders for large quantities of sample materials to meet increasing demand for pre-production quantum dots from customers and potential customers across the Company's target markets.

 

Nanoco also announces that the terms of its global licensing agreement with The Dow Chemical Company ("Dow") have been amended to accelerate the commercialisation of Nanoco's cadmium-free quantum dot technology in the display market.

 

Under the new terms, Dow continues to hold exclusive worldwide rights for the sale, marketing and manufacture of Nanoco's cadmium-free quantum dots for use in electronic displays.

 

Changes in the new agreement include the waiving of the requirement for Nanoco to contribute capital to the production plant Dow is preparing to build in Asia. In return, the royalty rate that Nanoco would receive from Dow's sale of quantum dots has been reduced to reflect the changes to the agreement. The adjusted royalties continue to acknowledge the proprietary value of Nanoco's technology. Financial details and other specifics are not being disclosed. The agreement does not include specifics about the anticipated price and volume of quantum dots as these are a function of commercial negotiations with customers. 

 

Dow and Nanoco have committed additional resources to accelerate commercialisation and full production under the licensing agreement is expected to begin in the first half of 2014.

 

Nanoco continues to make progress in its other core target markets of general lighting and solar energy. Notably, the Company's photovoltaic ink is now achieving an energy conversion efficiency of between 12 per cent and 13 per cent.

 

 

Michael Edelman, Nanoco's Chief Executive Officer, commented: "We have been delighted by the progress made by Dow. The amendments to the agreement with Dow better capitalise on our respective strengths and reinforce our collective commitment to commercialise this technology as quickly as possible to meet future market demand.

 

"We have also continued to make encouraging progress across our business, including a doubling of capacity at Runcorn to meet increasing demand for pre-production samples from display and other customers."

 

 

For further information:

 

Nanoco

+ 44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Colin White, Chief Financial Officer

Canaccord Genuity - Nomad and Joint Broker

+44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

Liberum Capital - Joint Broker

+44 (0) 20 3100 2000

Simon Atkinson

Richard Bootle

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes for editors:

 

About Nanoco Group plc

 

Nanoco is a world leader in the development and production of cadmium-free quantum dots for use in multiple applications including LCD displays, lighting and solar cells. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and business development offices in the USA, Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKADPDBKBBCB
Date   Source Headline
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Oct 20247:00 amRNSReceipt of General Meeting Requisition Notice
23rd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Oct 20247:00 amRNSAppointment of CEO and Notice of Results
22nd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
21st Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
18th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.